10004175 v02 Cholestech LDX_200311-1

1,2
LDX
12B1X10004000003

1, 2
• TC)
• HDLHDL)
• TRG)
• LDL
•
PRODUCT INFORMATION
LDX
LDX
• LDX
• LDX
• LDX
• LDX 40L
• LDX
•
•
1. Stone NJ et al. 2013 ACC/AHA guideline on the
treatment of blood cholesterol to reduce atherosclerotic
cardiovascular risk in adults: A Report of the American
College of Cardiology/American Heart Association Task
Force on Practice Guidelines. Circulation 2014; 129:S1-S45.
2.
of cardiovascular risk: A Report of the American College
of Cardiology/American Heart Association Task Force on
Practice Guidelines. Circulation 2014; 129:S49-S73.
3. Bulletin of the World Health Organization 2011;89:92-
101. High total serum cholesterol, medication coverage
and therapeutic control: an analysis of national health
examination survey data from eight countries. Fig. 3.
4. Christian JB et al. Cholesterol screening in US adults
and awareness of high cholesterol among individuals
with severe hypertriglyceridemia: National Health and
Nutrition Examination Surveys 2001- 2008. J Cardiovasc
Nurs. 2015; 30:26-34.
5. Muntner P et al. Trends in the prevalence, awareness,
treatment and control of high low density lipoproteincholesterol
among United States adults from 1999-2000
through 2009-2010. Am J Cardiol. 2013; 112:664-70.
6. Jones PH et al. Prevalence of dyslipidemia and lipid
goal attainment in statin-treated subjects from 3 data
sources: a retrospective analysis. J Am Heart Assoc. 2012;
1:e001800.
7. Haskell WL et al. Multifactor cardiovascular disease risk
reduction in medically underserved, high-risk patients.
Am J Cardiol 2006; 98:1472-9.
8.
and LDL cholesterol on atherosclerosis in diabetes: the
SANDS randomized trial. JAMA 2008; 299:1678-89.
9. Bluml BM et alJ. Pharmaceutical care services and results
in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc
(Wash) 2000; 40:157-65.
10.
intervention on cholesterol levels in patients at high risk of
cardiovascular events: the Second Study of Cardiovascular
Risk Intervention by Pharmacists (SCRIP-plus). Am J Med
2004; 116:130-3.
11. Gialamas A et al. Does point-of-care testing lead to the
same or better adherence to medication? A randomised
controlled trial: the PoCT in General Practice Trial. Med J
Aust. 2009; 191:487-91.
12. Laurence CO et al. Patient satisfaction with point-of-care
testing in general practice. Br J Gen Pract. 2010; 60:
e98-104.
アボット ダイアグノスティクス メディカル 株 式 会 社
〒270-2214 千 葉 県 松 戸 市 松 飛 台 357
フリーダイヤル:0120-1874-86( 受 付 時 間 :9:00~17:00 土 、 日 、 祝 日 を 除 く)
アボット ダイアグノスティクス メディカル 株 式 会 社 お 客 様 相 談 室
〒163-0807 東 京 都 新 宿 区 西 新 宿 2-4-1
© 2020 Abbott. All rights reserved. Abbott10004175-02 08/19